Metallicus Forms Advisory Board of Banking Regulatory and Compliance Experts
SAN FRANCISCO–(BUSINESS WIRE)–Metallicus, a leader in digital assets technologies, today announced the formation of its…
Year: 2022
CoreStack Announces Grand Opening of New Facility to Accelerate Product Development and Innovation
CoreStack’s New State-of-the-Art Office to Advance NextGen Cloud Governance Solution CHENNAI, India & BELLEVUE, Wash.–(BUSINESS…
Media Alert: Intel at Black Hat, Diana Initiative
Intel experts present briefings, theatre sessions and more at Black Hat USA 2022 and The…
KBRA Credit Profile Releases Research: Will Tuesday Morning Make It to the Weekend?
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA Credit Profile (KCP), a division of KBRA Analytics, releases research on CMBS…
Cadence Accelerates Hyperscale SoC Design with Industry’s First Verification IP and System VIP for CXL 3.0
Next-generation CXL VIP and System VIP tools provide faster path to testing and compliance with…
Radware Launches a New Cloud Security Center in Chile
Expands presence in Latin America MAHWAH, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) — Radware (NASDAQ:…
Zealand Pharma Hosts Conference Call on August 11 at 4 pm CET (10am ET) to Present Second Quarter Results for 2022
Company announcement – No. 31 / 2022 Zealand Pharma Hosts Conference Call on August 11 at…
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
Clinical Trial Now Expands to Fifteen U.S. Trial Sites HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE)…
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
— Company Receives FDA Fast Track Designation for VAX-24 in Adults — — Vaxcyte Completes…
SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
The CANDLE study met its primary endpoint, with 65.4% of patients with recurrent vulvovaginal candidiasis…
Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022
WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company…
Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company…
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference
ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial…
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study…
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical…
Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder
Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency…
Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10
COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) announced today…
Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a…
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of…